Zentalis Pharmaceuticals (NASDAQ:ZNTL) Releases Quarterly Earnings Results, Beats Estimates By $0.91 EPS

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) issued its quarterly earnings results on Tuesday. The company reported $0.14 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.77) by $0.91, Briefing.com reports. The firm had revenue of $40.56 million during the quarter, compared to analysts' expectations of $35.00 million. During the same quarter in the prior year, the firm earned ($1.07) EPS.

Zentalis Pharmaceuticals Price Performance

Shares of ZNTL traded up $0.12 during midday trading on Wednesday, reaching $12.43. 1,022,880 shares of the stock were exchanged, compared to its average volume of 783,921. The company has a market capitalization of $882.65 million, a price-to-earnings ratio of -2.70 and a beta of 1.82. Zentalis Pharmaceuticals has a twelve month low of $9.56 and a twelve month high of $31.46. The business's 50-day moving average price is $13.76 and its 200 day moving average price is $13.43.

Insider Activity at Zentalis Pharmaceuticals

In other Zentalis Pharmaceuticals news, CFO Melissa B. Epperly sold 2,573 shares of the business's stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $11.44, for a total value of $29,435.12. Following the completion of the sale, the chief financial officer now owns 451,449 shares in the company, valued at $5,164,576.56. The sale was disclosed in a document filed with the SEC, which is available through this link. Insiders own 6.10% of the company's stock.

Analyst Ratings Changes

Several equities analysts recently commented on ZNTL shares. Stifel Nicolaus dropped their target price on Zentalis Pharmaceuticals from $36.00 to $32.00 and set a "buy" rating on the stock in a report on Wednesday. HC Wainwright lowered their price objective on Zentalis Pharmaceuticals from $46.00 to $40.00 and set a "buy" rating for the company in a research report on Wednesday. Finally, Wedbush raised their target price on Zentalis Pharmaceuticals from $12.00 to $15.00 and gave the stock a "neutral" rating in a research report on Wednesday, February 28th. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat, Zentalis Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus target price of $37.14.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.